1 INTRODUCTION

Like whole blood, plasma is collected from healthy human donors. However, while much is known and has been written about whole blood donations and the worrisome trends that increasingly challenge its safety and global supply,^1-4 the complexities of plasma collection and its supply chain—from the donor's arm, through the manufacturing process, to the patient's therapy—have, with few exceptions,^5-8 received far less attention. Yet the biological medicines prepared from plasma represent a critical lifeline for an increasing number of patients worldwide.

中文翻译：

---

看不见的生命线：全球血浆供应的复杂性

 1 引言

与全血一样，血浆是从健康的人类供体中采集的。然而，尽管关于全血捐献以及日益挑战其安全性和全球供应的令人担忧的趋势已经知晓和撰写了很多文章，^1-4 但血浆采集及其供应链的复杂性——从捐献者的手臂，到制造过程，再到患者的治疗——除了少数例外，^5-8受到的关注要少得多。然而，由血浆制备的生物药物代表了全球越来越多的患者的关键生命线。